Clinically validated botulinum toxin type A (200U/vial) derived from Clostridium Botulinum CBFC26 strain, formulated with 99.5% active neurotoxin purity. FDA-complied manufacturing ensures 36-month stability at 2-8°C. Proven efficacy in 74% wrinkle reduction (Phase III trials) and 83% migraine relief in clinical applications.

PROPRIETARY TECHNOLOGY:

MEDICAL NOTICE: Results may vary ±15% based on individual neuromuscular response. Must be administered by board-certified practitioners. Contraindicated in 4.7% of patients with neuromuscular disorders. Always verify batch-specific potency data prior to use.